CARCINOMUL CU CELULE MERKEL

Metastatic cancer lymph nodes symptoms. Search Results

Conținutul

    specii de paraziți din corpul uman paraziti in corpul uman simptome

    Primary Outcome Measures: 1. To determine the profile of patients treated with Aromasin® age, type of tumour, type of surgery, hormone receptors, lymph node involvement, stage, grade, chemotherapy, radiotherapy 6 months 7.

    metastatic cancer lymph nodes symptoms

    To determine the profile of patients treated with Aromasin® age, type of tumour, type of surgery, hormone receptors, lymph node involvement, stage, grade, chemotherapy, radiotherapy 12 months 8. To determine the profile of patients treated with Aromasin® age, type of tumour, type of surgery, hormone receptors, lymph node involvement, stage, grade, chemotherapy, radiotherapy 18 months 9.

    metastatic cancer lymph nodes symptoms

    To determine the profile of patients treated with Aromasin® age, type of tumour, type of surgery, hormone receptors, lymph node involvement, stage, grade, chemotherapy, radiotherapy 24 months To determine the profile of patients treated with Aromasin® age, type of tumour, type of surgery, hormone receptors, lymph node involvement, stage, grade, chemotherapy, radiotherapy 30 months if applicable To determine the profile of patients treated with Aromasin® age, type of tumour, type of surgery, hormone receptors, lymph node involvement, stage, grade, chemotherapy, radiotherapy 36 months if applicable To evaluate compliance and the reasons for any discontinuation of Aromasin® therapy and the type of treatment administered afterwards hormonal therapy or chemotherapy 6 months To evaluate compliance and the reasons for any discontinuation of Aromasin® therapy and the type of treatment administered afterwards hormonal therapy or chemotherapy 12 months To evaluate compliance and the reasons for metastatic cancer lymph nodes symptoms discontinuation of Aromasin® therapy and the type of treatment administered afterwards hormonal therapy or chemotherapy 18 months To evaluate compliance and the reasons for any discontinuation of Aromasin® therapy and the type of treatment administered afterwards hormonal therapy or chemotherapy 24 months To evaluate compliance and the reasons for any discontinuation of Aromasin® therapy and the type of treatment administered afterwards hormonal therapy or chemotherapy 30 months if applicable To evaluate compliance and the reasons for any discontinuation of Aromasin® therapy and the type of treatment administered afterwards hormonal therapy or chemotherapy 36 metastatic cancer lymph nodes symptoms if applicable To evaluate the rate of treatment discontinuation 6 months To evaluate the rate of treatment discontinuation 12 months To evaluate the rate of treatment discontinuation 18 metastatic cancer lymph nodes symptoms To evaluate the rate of treatment discontinuation 24 months To evaluate the rate of treatment discontinuation 30 months if applicable To evaluate metastatic cancer lymph nodes symptoms rate of treatment human papillomavirus proteins 36 months if applicable To evaluate recurrence-free survival time from the inclusion to date of confirmation of any recurrence - as local or distant recurrence; new primary ipsilateral or controlateral breast cancer, death and time to disease progression.